HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
Read original at benzingaStocks · News reference
Voyager Therapeutics Presents Six‑Month Toxicology Data At AAIC Showing Investigational Alzheimer’s Gene Therapy VY1706 Was Well Tolerated And Cut Tau Protein Up To 75% In Primates
- Data presented as Developing Topics poster at AAIC 2026 -LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 13, 2026, 12:10 PM
- Checked
- Jul 13, 2026, 12:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Voyager Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate, Sales $3.165M Miss $4.728M Estimate
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 29.82 percent increase over losses of $(0.57) per share
Read original at benzinga8-K filing — Voyager Therapeutics, Inc. (VYGR)
Filed: 2026-07-13 AccNo: 0001104659-26-082906 Size: 197 KB Item 8.01: Other Events
Read original at edgar